Testing of a new antibody therapy using blood from children with B-cell Non-Hodgkin lymphoma.

Testing of a new antibody therapy using blood from children with B-cell Non-Hodgkin lymphoma. - Testing anti-CD20 IgA with blood from pediatric lymphoma patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53135

Enrollment

Registered

2018-01-25

Start date

2021-11-19

Completion date

Unknown

Last updated

2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Hodgkin B-cell lymphoma

Interventions

None listed

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: Diagnosis op B-Non-Hodgkin lymphoma is the inclusion criterium.

Exclusion criteria

Exclusion criteria: No diagnosis of B-Non-Hodgkin lymphoma.

Design outcomes

Primary

Measure	Time frame
Our in vitro experiments with patient material will demonstrate whether: 1. Our new anti-CD20 monoclonals are more effective in eliminating malignant CD20+ B cells. 2. IgA is superior to IgG in eliminating malignant CD20+ B-cells.	—

Secondary

Measure	Time frame
- Setting up of a qualitative and quantitative assay to measure B-cel depletion using lymphome and blood material from patients. - Determine the working mechanisms of anti-CD20 IgA mediated B-cel depletion (e.g. involvement of which leukocyte type(s) in ADCC).	—

Countries

Netherlands

Outcome results